
|Articles|January 18, 2022
Daily Medication Pearl: Brimonidine Tartrate/Timolol (Combigan)
Author(s)Saro Arakelians, PharmD
Combigan is comprised of 2 components that reduce elevated intraocular pressure, whether or not associated with glaucoma.
Advertisement
Medication Pearl of the Day: Brimonidine tartrate/timolol (Combigan)
Indication: Brimonidine tartrate/timolol (Combigan) is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Insight:
- Dosing: One drop in the affected eye(s), twice daily approximately 12 hours apart.
- Dosage forms: Solution containing 2 mg/mL brimonidine tartrate and 5 mg/mL timolol.
- Adverse events: Most common adverse reactions occurring in approximately 5% to 15% of patients include allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging
- Mechanism of action: Combigan is comprised of 2 components: brimonidine tartrate and timolol. Each of these components decreases elevated intraocular pressure, whether or not associated with glaucoma.
- Manufacturer: Allergan
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
3
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
4
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
5